ImmTAC

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Retrieved on: 
Venerdì, Maggio 31, 2024
PRAME, Bristol Myers Squibb, Patient, Infection, Rash, Progression-free survival, Immunocore, Research and development, Pembrolizumab, Transaminase, Gene expression, Translational research, PFS, Therapy, Neoplasm, RECIST, Cytokine release syndrome, ImmTAC, Event, PD-1, Cancer, ASCO, Research institute, OS, PR, Society, Immunohistochemistry, Melanoma, DCR, History, Autoimmune hepatitis, Nivolumab, Annual general meeting, CRS, Pharmaceutical industry

Brenetafusp was shown to be well tolerated, in monotherapy and in combination with anti-PD1, and demonstrated durable clinical benefit.

Key Points: 
  • Brenetafusp was shown to be well tolerated, in monotherapy and in combination with anti-PD1, and demonstrated durable clinical benefit.
  • “We expect brenetafusp PFS to be even higher in first-line based on our analysis of blood T cell fitness.
  • All monotherapy treated patients had received prior immune checkpoint inhibitors (100% anti-PD1, 81% anti-CTLA4).
  • Immunocore will host a conference call today, May 31, 2024 at 7:15 PM ET / 6:15 PM CT, to discuss the Phase 1 PRAME expansion data and Phase 3 registrational trial in cutaneous melanoma.

Immunocore reports first quarter financial results and provides a business update

Retrieved on: 
Mercoledì, Maggio 8, 2024
CTA, Total, Research, HLA, IND, ASCO, Research and development, BMY, Annual report, Drug, Autoimmune disease, APC, HIV, Bristol Myers Squibb, TCR, Autoimmunity, Infection, PRAME, Treatment, EMA, GMP, Clinical trial, Investigational New Drug, Platinum, ImmTAC, Nivolumab, Security (finance), Form 10-Q, Half-life, Patient, Immune system, Pharmaceutical industry

& ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Net loss for the first quarter of 2024 was $24.4 million compared to a net loss of $19.4 million in the same period in 2023.
  • The first quarter basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
  • This includes net cash proceeds of $390.2 million from the Company’s offering of convertible notes in February 2024.

Immunocore announces upcoming presentation and posters at ASCO 2024

Retrieved on: 
Mercoledì, Aprile 24, 2024
ImmTAC, Cancer, Nivolumab, Ipilimumab, Infection, Webcast, Immunocore, PRAME, ASCO, Patient, Society, Annual general meeting, Communications satellite

ET

Key Points: 
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.
  • ET
    Session: Poster Session – Melanoma/Skin Cancers, Saturday 1 June 2024, 1:30-4:30 p.m. CT / 12:30-3:30 p.m.

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Retrieved on: 
Giovedì, Febbraio 1, 2024
Liquid biopsy, MAF, Immunocore, Research, Clonal hematopoiesis, PALO, Patient, DELFI, TCR, ImmTAC, RUO, Neoplasm, Cancer, Plasma, Nucleic acid thermodynamics

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.

Key Points: 
  • PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay.
  • The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer.
  • Additionally, DELFI announced a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) – a commercial-stage biotechnology company pioneering the development of a novel class of bispecific T cell receptor (TCR) immunotherapies against cancer (ImmTAC molecules) – focused on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies.
  • "We are excited that Immunocore will be further exploring the clinical and research potential of the DELFI liquid biopsy platform as a new approach to monitoring treatment response."

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Retrieved on: 
Venerdì, Gennaio 5, 2024
Conference, ESMO, APC, PRAME, Treatment, Lung cancer, Immune system, IND, TCR, HBV, CMC, HLA, Melanoma, Nivolumab, Research, PIWIL1, Cancer, Standard of care, ImmTAC, Neoplasm, HIV, Ovary, PST, Webcast, Patient, Infection, Endometrium, CTA, Skin, Pharmaceutical industry

The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.

Key Points: 
  • The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
  • The Company has updated its corporate presentation to reflect these business and strategic updates.
  • Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
  • The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 10, 2023
Gastrointestinal cancer, PRAME, Patient, Ipilimumab, Commercial, IMC, Uveal melanoma, Infection, Research, MAD, Conference, Book, Safety, Abstract, DNA, AACR, HLA, Cancer, Record, BRAF, Medicine, Immunotherapy, TCR, CROI, James A. Schlipmann Melanoma Cancer Foundation, PIWIL1, Neoplasm, ImmTAC, Arm, HIV, OS, CTA, Fungal infection, Mum, Sale, ASCO, CTAS, American Society of Clinical Oncology, Melanoma, Annual general meeting, IND Queens Boulevard Line, Viral load, Society, Pharmaceutical industry, Cryptocurrency, Communications satellite, Immunocore, IL6

During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.

Key Points: 
  • During the first quarter of 2023, KIMMTRAK became the most prescribed medicine for HLA*02:01 positive patients with mUM with over half of patients in first line (1L) receiving KIMMTRAK.
  • In France and Germany, an estimated 80% and 70%, respectively, of first line HLA-A*02:01 positive patients with mUM treated in the first quarter received KIMMTRAK.
  • The Company launched KIMMTRAK in Austria and Israel in the first quarter and expects the commercial transition in Italy in the second quarter of this year.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND / CTA in the fourth quarter of 2023.

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Martedì, Aprile 18, 2023
AACR, Optimism, ERAP2, ERAP, Clinical trial, MHC, Cancer, Data collection, ERAP1, Research, TCR, Wolf, Neoplasm, ACTL8, American Association for Cancer Research, Therapy, ImmTAC, MHC class I, Pharmaceutical industry, Vaccine, Immunocore

OXFORD, England, April 17, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the presentation of new preclinical data on the company's potential first-in-class inhibitors of ERAP1 at the American Association of Cancer Research (AACR) Annual Meeting 2023. Presented data highlighted the ability of the company's ERAP1 inhibitors to generate and upregulate cancer antigens, creating novel therapeutic targets for combination with MHC Class I directed therapies, including an investigational T cell receptor (TCR) bispecific therapy. The study results were featured in an oral presentation (#3467) entitled, "First-in-class inhibitors of ERAP1: Generating antigens as novel targets for MHC1-directed therapies," at the AACR annual meeting, being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • OXFORD, England, April 17, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the presentation of new preclinical data on the company's potential first-in-class inhibitors of ERAP1 at the American Association of Cancer Research (AACR) Annual Meeting 2023.
  • The study results were featured in an oral presentation (#3467) entitled, "First-in-class inhibitors of ERAP1: Generating antigens as novel targets for MHC1-directed therapies," at the AACR annual meeting, being held April 14-19, 2023, in Orlando, Florida.
  • Data showed that ERAP1 inhibition upregulated, across multiple cancer types, the surface presentation of the ACTL8 cancer peptide that is targeted by the ImmTAC therapy.
  • "Grey Wolf continues to generate compelling preclinical data that support the therapeutic potential of ERAP1 inhibition in the treatment of cancer.

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

Retrieved on: 
Lunedì, Gennaio 9, 2023
IND, PRAME, PIWIL1, NSCLC, ImmTAC, Circulating tumor DNA, HBV, Neoplasm, GI, RECIST, Immunotherapy, Autoimmunity, HIV, DNA, Pancreatic cancer, Infection, Conference, ESMO, Webcast, TCR, Patient, CD3, Single, Cancer, HLE, Endometrial cancer, HLA-A24, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Q4, IMC, Immunocore, EU

In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.

Key Points: 
  • In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.
  • The IMC-F106C-101 trial is adaptive and enables combinations with standards-of-care including checkpoint inhibitors, chemotherapy, and tebentafusp.
  • The Company believes IMC-R117C is the first PIWIL1 targeted immunotherapy and plans to submit an IND in Q4 2023.
  • The Company plans to report data from the Single Ascending Dose portion of the Phase 1 HIV trial in 2023.

Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America

Retrieved on: 
Mercoledì, Novembre 9, 2022
Growth, Cytokine release syndrome, Infection, Melanoma, Chills, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PIM, Rash, Bispecific monoclonal antibody, Vomiting, Nasdaq, Autoimmune disease, Immunocore, Risk, Hypotension, EMA, Uveal melanoma, European Medicines Agency, Vital signs, Partnership, Fatigue, CRS, Creatinine, Fetus, Eye, ALT, FDA, ImmTAC, Anti-CD3 monoclonal antibody, Headache, Melanocyte, LATAM, AST, Edema, Breakthrough therapy, CEO, Food, Birth, Nausea, Patient, Abdominal pain, TGA, Health Canada, Cancer, Lymphocyte, Pascal (microarchitecture), TCR, Hypoxia, Xeroderma, Itch, Glucose, Pharmaceutical industry, Medical device, Medical imaging, Fever, Medison

PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease.

Key Points: 
  • "The expansion of our partnership with Immunocore into LATAM is a significant milestone in building our unified commercial platform in all international markets," says Meir Jakobsohn, Founder and CEO of Medison.
  • In this case, offering patients in Latin America hope in the form of a treatment for this rare and aggressive form of melanoma that affects the eye."
  • With this latest growth, Medison increases its commercial presence across Israel, Central and Eastern Europe, Canada, Asia-Pacific, South and Central America and the Caribbean countries.
  • Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

Immunocore Announces $140 Million Private Placement Financing

Retrieved on: 
Lunedì, Luglio 18, 2022
General Atlantic, TCR, Autoimmunity, Cancer, Infection, Investment, Hand, Security (finance), Nasdaq, U.S. Securities and Exchange Commission, Autoimmune disease, Safety, LP, PRAME, Private Securities Litigation Reform Act, Bill & Melinda Gates Foundation, Goal, ImmTAC, American depositary receipt, Securities Act of 1933, Melinda Gates, Exchange, PIPE, COVID-19, Sale, Company, Risk, Omicron, Annual report, Vaccine, Pharmaceutical industry, Immunocore

Immunocore anticipates that gross proceeds from the PIPE will be approximately $140 million, before deducting estimated offering expenses payable by the Company.

Key Points: 
  • Immunocore anticipates that gross proceeds from the PIPE will be approximately $140 million, before deducting estimated offering expenses payable by the Company.
  • The closing of the PIPE is expected to occur on or about July 20, 2022, subject to customary closing conditions.
  • The PIPE financing included participation from existing investors including RTW Investments, LP, Rock Springs Capital, and General Atlantic.
  • This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.